Effect of Smoking Cessation on the Pharmacokinetics and Pharmacodynamics of Clopidogrel after PCI: The Smoking Cessation Paradox StudyFunding This study was supported by a grant from the Centre of Postgraduate Medical Education (no. 501–1-10–14–16/17).
30 June 2019
15 November 2019
15 January 2020 (online)
Background Cigarette smoking is associated with enhanced clopidogrel effect and platelet inhibition. However, the effect of smoking cessation on clopidogrel pharmacokinetics (PK) and pharmacodynamics (PD) is unknown. We aimed to determine the effect of smoking cessation, confirmed by cotinine measurement, on clopidogrel PK and PD after percutaneous coronary intervention (PCI).
Methods and Results Following successful PCI, patients treated with 75 mg/day clopidogrel who reported smoking ≥10 cigarettes/day with NicAlert urine cotinine level 6 were enrolled. Clopidogrel and its metabolite concentrations, VerifyNow P2Y12 reaction units (PRUs), and NicAlert levels were measured in the study group before and at 30 days after smoking cessation and in a control group. CYP1A2 and CYP2C19 genotypes were determined. At 30-day visit (n = 87), 45 patients continued smoking, whereas 42 patients stopped smoking. Baseline PRUs were similar between groups. At 30 days, the smoking cessation group had higher PRUs (150.5 ± 68.6 vs. 118.4 ± 65.9, p = 0.03), greater absolute PRU change (27.7 ± 39.8 vs. −12.9 ± 55.4, p = 0.0002), greater change of PRUs adjusted for baseline platelet reactivity (38.6 ± 10.0, p < 0.01), greater risk of high platelet reactivity (HPR) (odds ratio: 10.14 [1.52–67.5], p = 0.017), and a trend towards decreased H3 clopidogrel metabolite levels (−3.41 ng/mL [−11.00 to 0.54 ng/mL], p = 0.072). CYP2C19 LoF carriers who stopped smoking had the highest PRUs, whereas those with the wild type who continued smoking had the lowest PRUs (p < 0.008).
Conclusion Smoking cessation in clopidogrel-treated patients after PCI is associated with increased platelet reactivity and greater risk of HPR. Alternative P2Y12 inhibitors may be considered in selected patients who stop smoking after PCI.
The work was performed at the Department of Cardiology, Centre of Postgraduate Medical Education, Grochowski Hospital, Warsaw, Poland.
- 1 Erhardt L. Cigarette smoking: an undertreated risk factor for cardiovascular disease. Atherosclerosis 2009; 205 (01) 23-32
- 2 Gurbel PA, Baker BA, Bailey WL, Bliden KP, Tantry US. Unravelling the smokers' paradox: cigarette smoking, high-risk coronary artery disease and enhanced clinical efficacy of oral P2Y12 inhibitors. Thromb Haemost 2014; 111 (06) 1187-1190
- 3 Swiger KJ, Yousuf O, Bliden KP, Tantry US, Gurbel PA. Cigarette smoking and clopidogrel interaction. Curr Cardiol Rep 2013; 15 (05) 361
- 4 Gurbel PA, Nolin TD, Tantry US. Clopidogrel efficacy and cigarette smoking status. JAMA 2012; 307 (23) 2495-2496
- 5 Gurbel PA, Bliden KP, Logan DK. , et al. The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study. J Am Coll Cardiol 2013; 62 (06) 505-512
- 6 Kazui M, Nishiya Y, Ishizuka T. , et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 2010; 38 (01) 92-99
- 7 Park KW, Park JJ, Jeon KH. , et al. Enhanced clopidogrel responsiveness in smokers: smokers' paradox is dependent on cytochrome P450 CYP1A2 status. Arterioscler Thromb Vasc Biol 2011; 31 (03) 665-671
- 8 Patti G, Polacco M, Taurino E, Gaudio C, Greco C. Effects of cigarette smoking on platelet reactivity during P2Y12 inhibition in patients with myocardial infarction undergoing drug-eluting stent implantation: results from the prospective cigarette smoking on platelet reactivity (COPTER) study. J Thromb Thrombolysis 2016; 41 (04) 648-653
- 9 Park KW, Kang SH, Kang J. , et al. Enhanced clopidogrel response in smokers is reversed after discontinuation as assessed by Verify Now assay: additional evidence for the concept of ‘smokers’ paradox'. Heart 2012; 98 (13) 1000-1006
- 10 Park MB, Kim CB, Nam EW, Hong KS. Does South Korea have hidden female smokers: discrepancies in smoking rates between self-reports and urinary cotinine level. BMC Womens Health 2014; 14: 156
- 11 Price MJ, Berger PB, Teirstein PS. , et al; GRAVITAS Investigators. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011; 305 (11) 1097-1105
- 12 Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107 (23) 2908-2913
- 13 Jeong YH, Bliden KP, Antonino MJ, Park KS, Tantry US, Gurbel PA. Usefulness of the VerifyNow P2Y12 assay to evaluate the antiplatelet effects of ticagrelor and clopidogrel therapies. Am Heart J 2012; 164 (01) 35-42
- 14 Tantry US, Bonello L, Aradi D. , et al; Working Group on On-Treatment Platelet Reactivity. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 2013; 62 (24) 2261-2273
- 15 Karaźniewicz-Łada M, Danielak D, Teżyk A, Zaba C, Tuffal G, Główka F. HPLC-MS/MS method for the simultaneous determination of clopidogrel, its carboxylic acid metabolite and derivatized isomers of thiol metabolite in clinical samples. J Chromatogr B Analyt Technol Biomed Life Sci 2012; 911: 105-112
- 16 Karaźniewicz-Łada M, Danielak D, Burchardt P. , et al. Clinical pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases. Clin Pharmacokinet 2014; 53 (02) 155-164
- 17 Giusti B, Gori AM, Marcucci R. , et al. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenet Genomics 2007; 17 (12) 1057-1064
- 18 Polakowska M, Kaleta D, Piotrowski W. , et al; On Behalf Of Wobasz Investigators; Multi-centre National Population Health Examination Survey (WOBASZ). Tobacco smoking in Poland in the years from 2003 to 2014. Pol Arch Intern Med 2017; 127 (02) 91-99
- 19 Ueno M, Ferreiro JL, Desai B. , et al. Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study. JACC Cardiovasc Interv 2012; 5 (03) 293-300
- 20 Kunutsor SK, Spee JM, Kieneker LM. , et al. Self-reported smoking, urine cotinine, and risk of cardiovascular disease: findings from the PREVEND (prevention of renal and vascular end-stage disease) prospective cohort study. J Am Heart Assoc 2018; 7 (10) e008726
- 21 Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. ; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345 (07) 494-502
- 22 Bhatt DL, Fox KA, Hacke W. , et al; CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354 (16) 1706-1717
- 23 Sibbing D, Bernlochner I, Kastrati A, Paré G, Eikelboom JW. Current evidence for genetic testing in clopidogrel-treated patients undergoing coronary stenting. Circ Cardiovasc Interv 2011; 4 (05) 505-513 , discussion 513
- 24 Brar SS, ten Berg J, Marcucci R. , et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. J Am Coll Cardiol 2011; 58 (19) 1945-1954
- 25 Mangiacapra F, Patti G, Peace A. , et al. Comparison of platelet reactivity and periprocedural outcomes in patients with versus without diabetes mellitus and treated with clopidogrel and percutaneous coronary intervention. Am J Cardiol 2010; 106 (05) 619-623
- 26 Geisler T, Zürn C, Simonenko R. , et al. Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions. Eur Heart J 2010; 31 (01) 59-66
- 27 Reed GW, Cannon CP, Waalen J. , et al. Influence of smoking on the antiplatelet effect of clopidogrel differs according to clopidogrel dose: Insights from the GRAVITAS trial. Catheter Cardiovasc Interv 2017; 89 (02) 190-198